What Is Ecnoglutide? Uses, Benefits, Safety, FDA Status, and Evidence
Medical review note: This article is for educational purposes only and does not provide medical advice. Ecnoglutide is not FDA-approved in the United States. Products sold online as ecnoglutide, XW003, Xianweiying, Xianyida, GLP-1 peptide, compounded GLP-1, or “research use only” ecnoglutide may carry serious safety, quality, legal, and regulatory risks.
Quick answer
Ecnoglutide is a once-weekly cAMP-biased glucagon-like peptide-1 receptor agonist, usually shortened to GLP-1 receptor agonist. It is also known as XW003 and was developed by Sciwind Biosciences. Ecnoglutide is approved in China for two indications: adult type 2 diabetes and chronic weight management in adults with overweight or obesity. It is not FDA-approved in the United States. Clinical trials in Chinese adults show HbA1c reduction in type 2 diabetes and clinically meaningful weight loss in adults with overweight or obesity. Its key differentiator is cAMP-biased GLP-1 signaling, which is intended to enhance GLP-1 receptor activity while reducing receptor desensitization, but long-term global safety, U.S. approval status, and broader real-world outcomes remain important open questions.
Key facts about Ecnoglutide
| Question | Answer |
|---|---|
| What is ecnoglutide? | A once-weekly cAMP-biased GLP-1 receptor agonist. |
| Other names | XW003, Xianweiying, Xianyida, ecnoglutide injection, GLP-1 analog. |
| Developer | Sciwind Biosciences. Pfizer has commercialization rights in mainland China. |
| Drug class | GLP-1 receptor agonist / cAMP-biased incretin analog / antidiabetic and weight-management peptide drug. |
| Main mechanism | Activates GLP-1 receptors with cAMP-biased signaling to improve glucose control, reduce appetite, promote satiety, slow gastric emptying, and support body-weight reduction. |
| FDA-approved? | No. Ecnoglutide is not FDA-approved in the United States. |
| China approval status | Approved by China’s NMPA for adult type 2 diabetes and chronic weight management in adults with overweight or obesity. |
| Main studied uses | Type 2 diabetes, obesity, overweight with weight-related risk, glycemic control, HbA1c reduction, body-weight reduction, and metabolic disease. |
| Human evidence level | Moderate to strong China-based phase 2 and phase 3 evidence for type 2 diabetes and weight management; U.S. approval and global outcomes data are not established. |
| Common side effects | Gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, abdominal discomfort, decreased appetite, and possible GLP-1 class risks. |
| Sports status | GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists. Athletes should verify current status through official anti-doping resources. |
| Main safety concern | Gastrointestinal tolerability, lack of FDA approval, GLP-1 class risks, unknown long-term global outcomes, and risks from unapproved online or research-use products. |
What is Ecnoglutide?
Ecnoglutide is a long-acting GLP-1 receptor agonist. It is designed as a once-weekly injectable peptide drug for metabolic disease.
Ecnoglutide is also known as:
- XW003
- Xianweiying
- Xianyida
- Ecnoglutide injection
Sciwind Biosciences describes ecnoglutide as the world’s first approved cAMP-biased GLP-1 receptor agonist. According to Sciwind, it has been approved in China for adult type 2 diabetes and adult chronic weight management in people with overweight or obesity.
A PubMed-indexed phase 2 diabetes study describes ecnoglutide as a novel, long-acting GLP-1 analog studied in adults with type 2 diabetes. A PubMed-indexed phase 3 obesity study describes ecnoglutide as a biased GLP-1 receptor agonist evaluated for overweight or obesity in Chinese adults.
The key distinction:
Ecnoglutide is not just another online GLP-1 peptide. It is a China-approved GLP-1 drug developed by Sciwind, but it is not FDA-approved in the United States.
How does Ecnoglutide work?
Ecnoglutide activates the GLP-1 receptor.
GLP-1 receptor activation can:
- Increase glucose-dependent insulin secretion
- Reduce inappropriate glucagon secretion
- Slow gastric emptying
- Reduce appetite
- Increase satiety
- Improve post-meal glucose control
- Reduce HbA1c in type 2 diabetes
- Support body-weight reduction
Ecnoglutide’s differentiator is cAMP-biased GLP-1 receptor signaling.
Sciwind describes ecnoglutide as selectively activating the cAMP pathway while reducing β-arrestin recruitment, which may reduce receptor internalization and desensitization. A PMC discovery paper describes ecnoglutide as a novel long-acting cAMP-biased GLP-1 analog developed for type 2 diabetes and obesity.
In plain English:
Ecnoglutide is designed to activate GLP-1 signaling in a way that may sustain strong metabolic effects over time.
That said, biased signaling is a mechanistic advantage claim. It does not automatically prove superior long-term outcomes versus semaglutide, tirzepatide, dulaglutide, liraglutide, or other GLP-1 drugs unless supported by head-to-head trials.
| Drug or candidate | Main receptor targets | Approval status |
|---|---|---|
| Ecnoglutide | GLP-1 receptor, cAMP-biased | Approved in China for type 2 diabetes and weight management; not FDA-approved. |
| Semaglutide | GLP-1 receptor | FDA-approved in different products for type 2 diabetes, obesity, and certain cardiovascular-risk indications. |
| Dulaglutide | GLP-1 receptor | FDA-approved for type 2 diabetes and certain cardiovascular-risk indications. |
| Liraglutide | GLP-1 receptor | FDA-approved in different products for type 2 diabetes and obesity. |
| Tirzepatide | GIP receptor + GLP-1 receptor | FDA-approved for type 2 diabetes, chronic weight management, and other specific indications. |
| Mazdutide | GLP-1 receptor + glucagon receptor | Approved in China for weight management and type 2 diabetes; not FDA-approved. |
| Retatrutide | GIP receptor + GLP-1 receptor + glucagon receptor | Investigational, not FDA-approved. |
The practical interpretation:
Ecnoglutide belongs in the GLP-1 receptor agonist category, with a cAMP-biased design that makes it mechanistically differentiated from older GLP-1 drugs.
What is Ecnoglutide used for?
Ecnoglutide is approved in China for adult type 2 diabetes and chronic weight management. It is not approved in the United States.
| Use | Evidence level | What is known | What is not known | |---|---|---| | Adult type 2 diabetes | Strong China phase 3 evidence / China-approved | Ecnoglutide is approved in China for adult type 2 diabetes and improves HbA1c. | It is not FDA-approved in the U.S.; global real-world outcomes remain limited. | | Chronic weight management | Strong China phase 3 evidence / China-approved | Ecnoglutide is approved in China for adult weight management in overweight or obesity. | U.S. FDA approval and long-term international outcomes are not established. | | Obesity / overweight | Strong China phase 3 evidence | SLIMMER phase 3 data showed significant weight loss in Chinese adults. | Comparative efficacy versus Wegovy, Zepbound, and other incretin drugs needs direct evidence. | | Type 2 diabetes with obesity | Moderate to strong evidence | GLP-1 therapy can improve glycemic control and reduce weight. | Specific long-term outcomes for diverse global populations need more evidence. | | Cardiovascular-risk reduction | Not established as approved indication | GLP-1 class drugs can have cardiovascular relevance. | Ecnoglutide does not have an established FDA cardiovascular outcomes indication. | | Fatty liver / MASH / NASH | Early or investigational | XW003 has been described as being developed for metabolic disease, including NASH in some early materials. | It is not approved for MASH, NASH, or liver disease. | | Anti-aging / longevity | Unsupported | Weight and glycemic control can improve metabolic risk in indicated populations. | Ecnoglutide is not an anti-aging or longevity therapy. | | Bodybuilding / casual cutting | Unsupported and medically inappropriate | Appetite and weight effects may attract misuse. | It is not a bodybuilding drug. | | Online research-use ecnoglutide | High risk | Sellers may market GLP-1-like peptides online. | Quality, sterility, identity, dose, and legality may be unknown. |
What does the research show?
China approval for type 2 diabetes
Ecnoglutide is approved in China for adult type 2 diabetes.
Sciwind announced that China’s National Medical Products Administration approved ecnoglutide injection for adult type 2 diabetes in January 2026. Reuters also reported that Sciwind’s injectable type 2 diabetes drug, ecnoglutide, was approved for use in China.
A Nature Communications phase 3 trial describes ecnoglutide as a cAMP-biased GLP-1 analog developed for type 2 diabetes and obesity and evaluated its efficacy and safety in adults with type 2 diabetes.
The practical interpretation:
Ecnoglutide is not merely theoretical. It has reached regulatory approval in China for adult type 2 diabetes.
China approval for chronic weight management
Ecnoglutide is also approved in China for chronic weight management.
Sciwind announced that ecnoglutide injection was approved by China’s NMPA for chronic weight management in adults with overweight or obesity. Reuters reported that China approved Pfizer’s GLP-1 receptor agonist drug Xianweiying, also known as ecnoglutide, for long-term weight management in overweight or obese adults.
The approval was supported by the SLIMMER phase 3 clinical trial in Chinese adults with overweight or obesity.
The practical interpretation:
Ecnoglutide is now a China-approved GLP-1 drug for both diabetes and weight management, but that status does not transfer to U.S. FDA approval.
Phase 3 obesity evidence
A Lancet Diabetes & Endocrinology phase 3 trial evaluated once-weekly ecnoglutide versus placebo for overweight or obesity in Chinese adults.
The PubMed record describes the trial as assessing the efficacy and safety of once-weekly ecnoglutide versus placebo for treatment of overweight or obesity in Chinese adults.
Reuters reported that the late-stage study showed roughly 10% to 15% average weight loss in treated patients, depending on dose and study details.
The practical interpretation:
Ecnoglutide has real late-stage obesity evidence, but most public late-stage evidence is concentrated in Chinese adults.
Phase 2 type 2 diabetes evidence
A PubMed phase 2 trial evaluated ecnoglutide in adults with type 2 diabetes in a randomized, double-blind, placebo-controlled study enrolling 145 adults.
The practical interpretation:
Phase 2 data supported further development for glycemic control, and the program later advanced to phase 3 and China approval.
Mechanistic and discovery evidence
A PMC discovery paper describes ecnoglutide as a long-acting, cAMP-biased GLP-1 analog and reports preclinical and early clinical evidence supporting development for type 2 diabetes and obesity.
The practical interpretation:
Ecnoglutide’s cAMP-biased mechanism is scientifically interesting, but direct clinical comparisons are still needed before claiming it is better than established GLP-1 or dual-incretin drugs.
Commercialization and Pfizer partnership
Sciwind partnered with Pfizer China to commercialize ecnoglutide in mainland China. Reuters reported that Pfizer signed a licensing agreement with Sciwind for ecnoglutide, with possible regulatory and sales milestones up to $495 million.
Reuters also reported that Pfizer’s GLP-1 weight-management drug Xianweiying, also known as ecnoglutide, became available for pre-order in China through JD.com.
The practical interpretation:
Ecnoglutide is moving from clinical development into commercial use in China, which makes current regulatory and pricing information important.
Evidence summary
| Claim | Evidence verdict | Explanation |
|---|---|---|
| “Ecnoglutide is a GLP-1 receptor agonist.” | Supported | It is a long-acting GLP-1 receptor agonist. |
| “Ecnoglutide is cAMP-biased.” | Supported | Sciwind and research literature describe it as a cAMP-biased GLP-1 analog. |
| “Ecnoglutide is the same as XW003.” | Supported | XW003 is the development name for ecnoglutide. |
| “Ecnoglutide is FDA-approved.” | False | Ecnoglutide is not FDA-approved in the United States. |
| “Ecnoglutide is approved in China.” | Supported | It is approved in China for adult type 2 diabetes and chronic weight management in adults with overweight or obesity. |
| “Ecnoglutide causes weight loss.” | Supported in clinical trials | Phase 3 obesity data showed significant weight reduction versus placebo. |
| “Ecnoglutide improves HbA1c.” | Supported in diabetes trials | Phase 2 and phase 3 data support glycemic-control effects. |
| “Ecnoglutide is the same as semaglutide.” | False | Both are GLP-1 receptor agonists, but they are different drugs with different structures and regulatory status. |
| “Ecnoglutide is the same as tirzepatide.” | False | Tirzepatide targets GIP and GLP-1 receptors; ecnoglutide targets GLP-1 receptors. |
| “Ecnoglutide has proven cardiovascular benefit.” | Not established | Dedicated cardiovascular outcomes evidence and FDA cardiovascular indication are not established. |
| “Research-use ecnoglutide is equivalent to approved ecnoglutide.” | False | Online research products may differ in identity, purity, sterility, dose, quality, and legality. |
Is Ecnoglutide FDA-approved?
No. Ecnoglutide is not FDA-approved in the United States.
There is no FDA-approved ecnoglutide product for:
- Type 2 diabetes
- Obesity
- Chronic weight management
- Prediabetes
- Fatty liver disease
- MASH or NASH
- Cardiovascular-risk reduction
- Anti-aging
- Bodybuilding
- Athletic performance
- General appetite suppression
- Longevity
- General wellness
However, ecnoglutide is approved in China for:
- Adult type 2 diabetes
- Chronic weight management in adults with overweight or obesity
The key distinction:
China approval is real, but it is not U.S. FDA approval.
Is Ecnoglutide legal?
Ecnoglutide’s legal status depends on country, prescription status, product type, and intended use.
For U.S. readers:
Ecnoglutide is not FDA-approved, and online availability does not mean it is legally marketed for human therapeutic use.
For China readers:
Ecnoglutide has regulatory approval for adult type 2 diabetes and adult chronic weight management under China’s NMPA approval framework.
A legitimate approved product in China is different from an online “research use only” peptide.
The practical distinction:
| Product type | What it means |
|---|---|
| China-approved ecnoglutide | Regulated product approved by China’s NMPA for specific indications. |
| FDA-approved ecnoglutide | Does not currently exist. |
| Clinical-trial ecnoglutide | Investigational product used under monitored study protocols. |
| Research-use ecnoglutide | Not an FDA-approved consumer therapeutic product. |
| Online GLP-1 peptide | Higher risk for identity, purity, sterility, dose, and safety problems. |
The blunt version:
Buying “research use only” ecnoglutide online is not the same as receiving an approved GLP-1 medication from a legitimate pharmacy.
Is Ecnoglutide banned in sports?
Ecnoglutide is a GLP-1 receptor agonist. GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists.
The USADA GLP-1 athlete guide says GLP-1 drugs are not currently prohibited in sport, but WADA is monitoring and evaluating GLP-1 agonist use by athletes.
The WADA GLP-1 receptor agonist monitoring research page discusses monitoring of GLP-1 receptor agonists.
The practical advice:
Athletes should verify ecnoglutide through Global DRO, WADA, or USADA before use and should avoid unapproved online GLP-1 products.
Safety and side effects
Ecnoglutide has real pharmacologic activity. It should not be treated like a harmless peptide.
Common or likely side effects, based on ecnoglutide clinical studies and GLP-1 class patterns, may include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal discomfort
- Dyspepsia
- Decreased appetite
- Injection-site reactions
- Dizziness
- Dehydration risk from severe vomiting or diarrhea
- Possible hypoglycemia risk when combined with insulin or insulin secretagogues
- Possible gallbladder-related concerns by GLP-1 class analogy
- Possible pancreatitis-related concerns by GLP-1 class analogy
- Unknown long-term cardiovascular outcomes
- Unknown rare adverse-event profile across broad global populations
- Product-quality and sterility risks from online sources
Because ecnoglutide is a GLP-1 receptor agonist, safety evaluation should consider GLP-1 class concerns, including gastrointestinal tolerability, pancreatitis warnings, gallbladder disease, dehydration-related kidney injury, and hypoglycemia risk when combined with certain diabetes medications.
A serious evaluation of ecnoglutide should separate:
| Product type | Risk profile |
|---|---|
| China-approved ecnoglutide | Regulated prescription product under China approval conditions. |
| Clinical-trial ecnoglutide | Investigational product used under monitored research protocols. |
| Future FDA-approved ecnoglutide | Would require FDA-approved labeling, manufacturing, and safety review. |
| Online research-use ecnoglutide | High risk for identity, purity, sterility, dosing, and legal problems. |
Ecnoglutide vs similar GLP-1 drugs and peptides
| Compound | Category | Main difference |
|---|---|---|
| Ecnoglutide / XW003 | cAMP-biased GLP-1 receptor agonist | Approved in China for adult type 2 diabetes and weight management; not FDA-approved. |
| Semaglutide / Ozempic | GLP-1 receptor agonist | FDA-approved for type 2 diabetes and certain cardiovascular-risk uses. |
| Semaglutide / Wegovy | GLP-1 receptor agonist | FDA-approved chronic weight-management GLP-1 product. |
| Dulaglutide / Trulicity | GLP-1 receptor agonist | FDA-approved for type 2 diabetes and certain cardiovascular-risk indications, not obesity. |
| Liraglutide / Victoza | GLP-1 receptor agonist | Once-daily FDA-approved diabetes GLP-1 drug. |
| Liraglutide / Saxenda | GLP-1 receptor agonist | Once-daily FDA-approved obesity GLP-1 drug. |
| Tirzepatide / Mounjaro | GIP/GLP-1 receptor agonist | FDA-approved for type 2 diabetes; dual receptor mechanism. |
| Tirzepatide / Zepbound | GIP/GLP-1 receptor agonist | FDA-approved for chronic weight management and other specific indications. |
| Mazdutide | GLP-1/glucagon receptor agonist | Approved in China; dual receptor mechanism, not FDA-approved. |
| Retatrutide | GIP/GLP-1/glucagon receptor agonist | Investigational triple agonist, not FDA-approved. |
| Albiglutide | GLP-1 receptor agonist | Former FDA-approved diabetes drug, discontinued in the U.S. |
The key distinction:
Ecnoglutide is a cAMP-biased GLP-1 receptor agonist with China approvals, not a U.S. FDA-approved GLP-1 medication and not a generic research peptide.
Why is Ecnoglutide sold as “research use only”?
Some online sellers may use “research use only” language to sell ecnoglutide or GLP-1-like peptides outside normal prescription channels.
That label is not a trust signal.
A serious reader should understand this distinction:
| Product type | What it means |
|---|---|
| China-approved ecnoglutide | Regulated product approved by China’s NMPA for specific indications. |
| FDA-approved ecnoglutide | Does not currently exist. |
| Clinical-trial ecnoglutide | Investigational product used under monitored protocols. |
| Research-use ecnoglutide | Not an FDA-approved consumer therapeutic product. |
| Online GLP-1 peptide | Higher risk for identity, purity, sterility, dose, and authenticity problems. |
| “Weight-loss ecnoglutide” online | Misleading unless it is a regulated product in a jurisdiction where it is approved and lawfully dispensed. |
How to evaluate Ecnoglutide claims online
| Claim | What to verify |
|---|---|
| “FDA-approved ecnoglutide” | False. Ecnoglutide is not FDA-approved in the U.S. |
| “Approved ecnoglutide” | Approved where? China approval is real, but jurisdiction and indication matter. |
| “Same as Ozempic” | False. Ozempic is semaglutide. Ecnoglutide is a different GLP-1 receptor agonist. |
| “Same as Wegovy” | False. Wegovy is semaglutide and FDA-approved for chronic weight management. |
| “Same as Mounjaro” | False. Mounjaro is tirzepatide, a GIP/GLP-1 receptor agonist. |
| “Better than semaglutide” | Not established without direct, peer-reviewed head-to-head evidence. |
| “Proven cardiovascular benefit” | Not established. Look for dedicated cardiovascular outcomes trials. |
| “Safe for everyone” | False. GI effects, GLP-1 class risks, and contraindication-like concerns matter. |
| “Research use only” | This does not mean safe, legal, approved, or appropriate for human use. |
| “Cheap ecnoglutide online” | High risk. Product identity, sterility, purity, dose, and safety may be unknown. |
| “Safe for athletes” | Verify through WADA, USADA, or Global DRO. GLP-1 rules can change. |
| “Anti-aging peptide” | Unsupported as a drug claim. Ecnoglutide is a metabolic drug, not a longevity therapy. |
Bottom line
Ecnoglutide is a once-weekly cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences. It is approved in China for adult type 2 diabetes and chronic weight management in adults with overweight or obesity. Clinical trials show meaningful HbA1c reduction and weight-loss effects.
The most defensible conclusion is:
Ecnoglutide is a serious China-approved metabolic drug, not a casual research peptide. It is not FDA-approved in the United States, and readers should distinguish regulated China-approved ecnoglutide from unapproved online products with uncertain identity, purity, sterility, dose, and legal status.
FAQ
What is Ecnoglutide?
Ecnoglutide is a once-weekly cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences. It is also known as XW003.
What is XW003?
XW003 is the development name for ecnoglutide.
Is Ecnoglutide FDA-approved?
No. Ecnoglutide is not FDA-approved in the United States.
Is Ecnoglutide approved in China?
Yes. Ecnoglutide is approved in China for adult type 2 diabetes and chronic weight management in adults with overweight or obesity.
What is Ecnoglutide used for?
In China, ecnoglutide is approved for adult type 2 diabetes and chronic weight management in adults with overweight or obesity.
How does Ecnoglutide work?
Ecnoglutide activates GLP-1 receptors with cAMP-biased signaling. It helps improve glucose control, reduce appetite, increase satiety, slow gastric emptying, and support body-weight reduction.
Is Ecnoglutide the same as Ozempic?
No. Ozempic contains semaglutide. Ecnoglutide and semaglutide are both GLP-1 receptor agonists, but they are different drugs.
Is Ecnoglutide the same as Wegovy?
No. Wegovy is semaglutide and is FDA-approved for chronic weight management. Ecnoglutide is a different GLP-1 receptor agonist approved in China, not FDA-approved in the U.S.
Is Ecnoglutide the same as Mounjaro?
No. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Ecnoglutide is a GLP-1 receptor agonist.
Does Ecnoglutide cause weight loss?
Yes, clinical trials show that ecnoglutide can produce clinically meaningful weight loss in adults with overweight or obesity. It is approved in China for chronic weight management.
Does Ecnoglutide help type 2 diabetes?
Yes. Ecnoglutide improves glycemic control and is approved in China for adult type 2 diabetes.
Is Ecnoglutide safe?
Ecnoglutide has clinical-trial safety data, but it is not risk-free. Common concerns include gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite. Long-term global real-world safety data are still developing.
Is Ecnoglutide legal in the U.S.?
Ecnoglutide is not FDA-approved in the U.S. Online sales as a research peptide do not mean it is legally marketed for human therapeutic use.
Is Ecnoglutide banned in sports?
GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists. Athletes should verify ecnoglutide status through WADA, USADA, or Global DRO before use.
Why do sellers call Ecnoglutide “research use only”?
Sellers often use “research use only” language because their ecnoglutide products are not FDA-approved consumer therapeutic products. The phrase does not make the product safe, legal, approved, or clinically proven.
What is the biggest risk with Ecnoglutide?
The biggest risks are using a non-FDA-approved metabolic drug without medical supervision, confusing China approval with U.S. approval, and buying online products with uncertain identity, purity, sterility, concentration, and safety.
Sources
- Sciwind Biosciences: Ecnoglutide Approved by China’s NMPA for Chronic Weight Management
- Sciwind Biosciences: Ecnoglutide Approved by China’s NMPA for Adult Type 2 Diabetes
- Reuters: China Approves Pfizer GLP-1 Drug for Weight Management
- Reuters: Sciwind Biosciences Diabetes Drug Approved in China
- Reuters: Pfizer in Diabetes Drug Deal with Sciwind Biosciences
- Reuters: Pfizer GLP-1 Weight Loss Drug Available for Pre-order in China
- PubMed: Efficacy and Safety of GLP-1 Analog Ecnoglutide in Adults With Type 2 Diabetes
- Nature Communications: Efficacy and Safety of cAMP Signalling-Biased GLP-1 Analog Ecnoglutide in Type 2 Diabetes
- PubMed: Efficacy and Safety of a Biased GLP-1 Receptor Agonist Ecnoglutide in Overweight or Obesity
- Lancet Diabetes & Endocrinology: Ecnoglutide for Overweight or Obesity in Chinese Adults
- PMC: Discovery of Ecnoglutide, a Novel Long-Acting cAMP-Biased GLP-1 Analog
- PubMed: Discovery of Ecnoglutide, a Novel Long-Acting cAMP-Biased GLP-1 Analog
- ClinicalTrials.gov: XW003 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study
- Sciwind Biosciences Pipeline: Ecnoglutide
- USADA: Weight Loss Drugs, What Athletes Need to Know About GLP-1s
- WADA: GLP-1 Receptor Agonists Monitoring Research
- WADA: Prohibited List
Frequently asked questions
What is Ecnoglutide?
Ecnoglutide is a once-weekly cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences. It is also known as XW003.
What is XW003?
XW003 is the development name for ecnoglutide.
Is Ecnoglutide FDA-approved?
No. Ecnoglutide is not FDA-approved in the United States.
Is Ecnoglutide approved in China?
Yes. Ecnoglutide is approved in China for adult type 2 diabetes and chronic weight management in adults with overweight or obesity.
How does Ecnoglutide work?
Ecnoglutide activates GLP-1 receptors with cAMP-biased signaling. It helps improve glucose control, reduce appetite, increase satiety, slow gastric emptying, and support body-weight reduction.
Is Ecnoglutide the same as Ozempic?
No. Ozempic contains semaglutide. Ecnoglutide and semaglutide are both GLP-1 receptor agonists, but they are different drugs.
Is Ecnoglutide the same as Mounjaro?
No. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Ecnoglutide is a GLP-1 receptor agonist.
Does Ecnoglutide cause weight loss?
Yes, clinical trials show that ecnoglutide can produce clinically meaningful weight loss in adults with overweight or obesity. It is approved in China for chronic weight management.
Does Ecnoglutide help type 2 diabetes?
Yes. Ecnoglutide improves glycemic control and is approved in China for adult type 2 diabetes.
Is Ecnoglutide safe?
Ecnoglutide has clinical-trial safety data, but it is not risk-free. Common concerns include gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite. Long-term global real-world safety data are still developing.
Is Ecnoglutide banned in sports?
GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists. Athletes should verify ecnoglutide status through WADA, USADA, or Global DRO before use.
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]Sciwind Biosciences Pipeline: Ecnoglutide
Company Pipeline
- [15]
- [16]
- [17]WADA: Prohibited List
Anti Doping
Last updated May 9, 2026